Farmers Trust Co. Increases Holdings in Biogen Inc. $BIIB

Farmers Trust Co. boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 27.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,185 shares of the biotechnology company’s stock after purchasing an additional 7,214 shares during the period. Farmers Trust Co.’s holdings in Biogen were worth $5,840,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Biogen during the second quarter worth about $25,000. Rothschild Investment LLC grew its stake in shares of Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares in the last quarter. Accredited Wealth Management LLC raised its holdings in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC lifted its position in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Guggenheim increased their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research report on Monday, February 9th. HSBC boosted their target price on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday. BMO Capital Markets raised their price target on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a report on Friday, February 6th. TD Cowen lifted their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Wolfe Research set a $231.00 price objective on shares of Biogen in a report on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and an average price target of $205.31.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Late‑breaking Phase 2 AMETHYST Part A data for litifilimab in cutaneous lupus (CLE) will be presented at the AAD meeting; the program already has FDA Breakthrough Therapy designation, which could materially increase the drug’s commercial value if further data confirm benefit. Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data
• Positive Sentiment: Biogen launched a Phase 3 fumarate study targeting pediatric multiple sclerosis, expanding potential addressable market and signaling management’s push for growth outside its core older-adult neurology franchises. Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study
• Positive Sentiment: BIIB080 Phase 1 imaging study completed — an early but necessary step in the Alzheimer’s program that reduces some development uncertainty and keeps the pipeline moving. Biogen’s BIIB080 Imaging Study Completes
• Positive Sentiment: An HSBC write‑up forecasting strong price appreciation for BIIB may bolster sentiment and buying interest from institutional investors. HSBC Forecasts Strong Price Appreciation for Biogen
• Neutral Sentiment: Biogen presented at the Stifel 2026 Virtual CNS Forum (investor transcript available) — useful for detail but unlikely to move the stock unless new guidance or surprises emerged. Biogen Presents at Stifel 2026 Virtual CNS Forum Transcript
• Neutral Sentiment: Short‑interest notices report a “significant increase” in March but show 0 shares / NaN change and a days‑to‑cover of 0.0 — the data look inconsistent, so treat any short‑pressure signal as uncertain until corrected.
• Negative Sentiment: The U.S. District Court for the District of Massachusetts certified a securities class action on behalf of Biogen purchasers, which introduces legal risk, potential costs and headline volatility. Securities Litigation Certified as Class Action

Biogen Price Performance

BIIB stock opened at $183.49 on Friday. The stock’s 50 day moving average is $184.18 and its two-hundred day moving average is $168.12. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $202.41. The company has a market capitalization of $26.93 billion, a PE ratio of 20.83, a P/E/G ratio of 1.45 and a beta of 0.15. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the business posted $3.44 EPS. The business’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.18% of the stock is owned by corporate insiders.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.